| |||||
Chemotherapy Options in the Management of Platinum-Sensitive Recurrent Ovarian Cancer | |||||
Sunday, August 15, 2010
Chemotherapy Options in the Management of Platinum-Sensitive Recurrent Ovarian Cancer
abstract: Expert Opinion on Drug Metabolism & Toxicology - Effects of herbal products on the metabolism and transport of anticancer agents
What the reader will gain: Potential interactions of herbal medicines with anticancer agents have become a safety concern in cancer chemotherapy.
Take home message: Further studies are warranted to investigate the efficacy and safety profiles of herbal medicines commonly used by cancer patients.
full free access: A KRAS-Variant in Ovarian Cancer Acts as a Genetic Marker of Cancer Risk — Cancer Res
Note: in research; discusses HBOC (BRCA/mutation not found); KRAS has been studied extensively in colorectal cancer but not mentioned in this research eg. Lynch Syndrome
Medicine, Health Care and Philosophy A European Journal Editorial: The language of medicine and bioethics
"...The contributions in this section clearly show the new stage in the development of global bioethics, with an increasing body of documents, guidelines, publications at the level of international law. The language of human rights is becoming the new language of bioethics."
How do you rank and use medical evidence? short discussion on clinical trials
Randomized clinical trials are the gold standard ; Mixed bag of evidence to determine drug safety
The Cancer Biomarker Conundrum: Too Many False Discoveries
The Cancer Biomarker Conundrum: Too Many False Discoveries
14 Aug 2010
"The boom in cancer biomarker investments over the past 25 years has not translated into major clinical success. The reasons for biomarker failures include problems with study design and interpretation, as well as statistical deficiencies, according to an article published online August 12 in The Journal of the National Cancer Institute...".cont'd including several references to ovarian cancer
Subscribe to:
Posts
(
Atom
)
Posts
